文献速递眼底病与葡萄膜炎

溴莫尼定给药系统(Brimo DDS)第一代治疗地图样萎缩的2期安全性及疗效研究

PHASE 2 STUDY OF THE SAFETY AND EFFICACY OF BRIMONIDINE DRUG DELIVERY SYSTEM (BRIMO DDS) GENERATION 1 IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION.
PubMed 文献 · Retina · 2021-01-01

这项2期随机双盲多中心24个月研究评估了玻璃体内植入Brimo DDS(132 µg或264 µg)对比假手术治疗继发于年龄相关性黄斑变性的地图样萎缩的安全性和疗效。第12个月时,132 µg组、264 µg组和假手术组的GA面积平均增长分别为1.78 mm2、1.59 mm2和2.19 mm2;第3个月时Brimo DDS两剂量组GA面积增长均显著小于假手术组(P ≤ 0.032)。在基线病灶面积≥6 mm2的患者中,第12个月时Brimo DDS 132 µg和264 µg组GA病灶面积和有效半径增长较假手术组减少(P ≤ 0.050)。

要点

  • Brimo DDS 132 µg和264 µg在第3个月时GA面积增长显著小于假手术组(P ≤ 0.032)。
  • 基线GA病灶面积≥6 mm2患者中,第12个月Brimo DDS两剂量组病灶增长较假手术减少(P ≤ 0.050)。
  • 治疗相关不良事件通常与注射操作相关。

核心结论

  • Brimo DDS具有良好的安全性特征,并在第3个月减少GA病灶面积增长。
  • 在基线GA病灶面积≥6 mm2的患者中,第12个月时Brimo DDS 132 µg和264 µg组的病灶增长减少。
  • 结果支持开展3期研发。

研究设计与样本

  • 2期、随机、多中心、双盲、24个月研究。
  • 研究眼接受Brimo DDS 132 µg(n = 49)、Brimo DDS 264 µg(n = 41)或假手术(n = 23)治疗(第1天给药;第6个月再次治疗)。
  • 疗效分析主要时间点为第12个月。

主要发现

  • 第12个月时,Brimo DDS 132 µg组、264 µg组和假手术组的GA面积平均增长分别为1.78 mm2、1.59 mm2和2.19 mm2。
  • Brimo DDS 132 µg和264 µg组的GA面积增长持续小于假手术组;第3个月时组间差异显著(P ≤ 0.032)。
  • 在基线病灶面积≥6 mm2的患者(占三分之二)中,第12个月时Brimo DDS 132 µg和264 µg组的GA病灶面积和有效半径增长较假手术组减少(P ≤ 0.050)。
  • 治疗相关不良事件通常与注射操作相关。

临床怎么用

  • 对于继发于年龄相关性黄斑变性的地图样萎缩,Brimo DDS可能减少GA病灶面积增长,尤其在基线病灶面积≥6 mm2的患者中。
  • 治疗相关不良事件多与注射操作相关,需关注注射安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the safety and efficacy of Brimonidine Drug Delivery System (Brimo DDS), a biodegradable intravitreal implant, in the treatment of geographic atrophy (GA) secondary to age-related macular degeneration. METHODS: Phase 2, randomized, multicenter, double-masked, 24-month study. Study eyes were treated (Day 1; Month 6 retreatment) with Brimo DDS 132 µg (n = 49), Brimo DDS 264 µg (n = 41), or sham procedure (n = 23). The primary timepoint for efficacy analysis was Month 12. RESULTS: Mean GA area growth at Month 12 was 1.78 mm2, 1.59 mm2, and 2.19 mm2 in the Brimo DDS 132 µg, 264 µg, and sham groups, respectively. Geographic atrophy area growth was consistently smaller with Brimo DDS 132 and 264 µg than sham; between-group differences were significant (P ≤ 0.032) at Month 3. In patients with baseline lesion area ≥6 mm2 (two-thirds of patients), GA lesion area and effective radius growth was reduced with Brimo DDS 132 and 264 µg at Month 12 (P ≤ 0.050 vs. sham). Treatment-related adverse events were usually injection procedure-related. CONCLUSION: Brimo DDS demonstrated a favorable safety profile and reduced GA lesion area growth at Month 3. Lesion growth at Month 12 was reduced in patients with baseline GA lesion area ≥6 mm2. The results support Phase 3 development.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Kuppermann BD, Patel SS, Boyer DS, et al. PHASE 2 STUDY OF THE SAFETY AND EFFICACY OF BRIMONIDINE DRUG DELIVERY SYSTEM (BRIMO DDS) GENERATION 1 IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION. Retina. 2021. PMID: 32134802. doi:10.1097/IAE.0000000000002789

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。